Theravance Biopharma Reports Positive Results from Phase 1 Clinical Trial of TD-8236, an Investigational, Lung-Selective, Inhaled Pan-Janus Kinase (JAK) Inhibitor for Inflammatory Lung Diseases

DUBLIN, Sept. 9, 2019 /PRNewswire/ — Theravance Biopharma, Inc. (NASDAQ: TBPH) (“Theravance Biopharma” or the “Company”) today announced initial results, including positive biomarker responses, from its Phase 1 single-ascending dose (SAD) and multiple-ascending dose (MAD) clinical trial…

Source: https://www.prnewswire.com:443/news-releases/theravance-biopharma-reports-positive-results-from-phase-1-clinical-trial-of-td-8236-an-investigational-lung-selective-inhaled-pan-janus-kinase-jak-inhibitor-for-inflammatory-lung-diseases-300913805.html